Myriad Genetics reported Q3 results and raised the midpoint of its 2026 revenue guidance, signaling a firmer business outlook. The update follows the sale of it

Myriad Genetics reported Q3 results and raised the midpoint of its 2026 revenue guidance, signaling a firmer business outlook. The update follows the sale of its Prenatal Health unit to Labcorp and oncology partnerships with SOPHiA GENETICS and AstraZeneca.